Natural killer cells modulation in hematological malignancies

被引:35
作者
Baier, Celine [1 ,2 ]
Fino, Aurore [1 ,2 ]
Sanchez, Carole [1 ]
Famault, Laure [1 ,3 ]
Rihet, Pascal [1 ,2 ]
Kahn-Perles, Brigitte [1 ,2 ]
Costello, Regis T. [1 ,2 ,3 ]
机构
[1] INSERM, TAGC, UMR1090, F-13258 Marseille, France
[2] Aix Marseille Univ, TAGC, UMR1090, Marseille, France
[3] Hop Conception, APHM, Serv Hematol, F-13005 Marseille, France
关键词
hematological malignancies; natural killer cells; natural cytotoxicity receptors; immune escape; immunotherapy;
D O I
10.3389/fimmu.2013.00459
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Hematological malignancies (HM) treatment improved over the last years resulting in increased achievement of complete or partial remission, but unfortunately high relapse rates are still observed, due to remaining minimal residual disease. Therefore, sustainment of long-term remission is crucial, using either drug maintenance treatment or by boosting or prolonging an immune response. Immune system has a key role in tumor surveillance. Nonetheless, tumor-cells evade the specific T-lymphocyte mediated immune surveillance using many mechanisms but especially by the down-regulation of the expression of HLA class I antigens. In theory, these tumor-cells lacking normal expression of HLA class I molecules should be destroyed by natural killer (NK) cells, according to the missing-self hypothesis. NK cells, at the frontier of innate and adaptive immune system, have a central role in tumor-cells surveillance as demonstrated in the setting of allogenic stem cell transplantation. Nevertheless, tumors develop various mechanisms to escape from NK innate immune pressure. Abnormal NK cytolytic functions have been described in many HM. We present here various mechanisms involved in the escape of HM from NK-cell surveillance, i.e., NK-cells quantitative and qualitative abnormalities.
引用
收藏
页数:8
相关论文
共 94 条
[1]  
Alici E, 2010, CURR OPIN MOL THER, V12, P724
[2]   Monocytic AML cells inactivate antileukemic lymphocytes: role of NADPH oxidase/gp91phox expression and the PARP-1/PAR pathway of apoptosis [J].
Aurelius, Johan ;
Thoren, Fredrik B. ;
Akhiani, Ali A. ;
Brune, Mats ;
Palmqvist, Lars ;
Hansson, Markus ;
Hellstrand, Kristoffer ;
Martner, Anna .
BLOOD, 2012, 119 (24) :5832-5837
[3]   Glucocorticoid-Induced Tumor Necrosis Factor Receptor-Related Protein Ligand Subverts Immunosurveillance of Acute Myeloid Leukemia in Humans [J].
Baessler, Tina ;
Krusch, Matthias ;
Schmiedel, Benjamin Joachim ;
Kloss, Mercedes ;
Baltz, Katrin Miriam ;
Wacker, Alexander ;
Schmetzer, Helga Maria ;
Salih, Helmut Rainer .
CANCER RESEARCH, 2009, 69 (03) :1037-1045
[4]   Tumour-derived microvesicles modulate biological activity of human monocytes [J].
Baj-Krzyworzeka, Monika ;
Szatanek, Rafal ;
Weglarczyk, Kazimierz ;
Baran, Jaroslaw ;
Zembala, Marek .
IMMUNOLOGY LETTERS, 2007, 113 (02) :76-82
[5]   Identification of a cellular ligand for the natural cytotoxicity receptor NKp44 [J].
Baychelier, Florence ;
Sennepin, Alexis ;
Ermonval, Myriam ;
Dorgham, Karim ;
Debre, Patrice ;
Vieillard, Vincent .
BLOOD, 2013, 122 (17) :2935-2942
[6]   A phase 1 trial of the anti-KIR antibody IPH2101 in patients with relapsed/refractory multiple myeloma [J].
Benson, Don M., Jr. ;
Hofmeister, Craig C. ;
Padmanabhan, Swaminathan ;
Suvannasankha, Attaya ;
Jagannath, Sundar ;
Abonour, Rafat ;
Bakan, Courtney ;
Andre, Pascale ;
Efebera, Yvonne ;
Tiollier, Jerome ;
Caligiuri, Michael A. ;
Farag, Sherif S. .
BLOOD, 2012, 120 (22) :4324-4333
[7]   Safety, Pharmacokinetics, and Immunomodulatory Effects of Lenalidomide in Children and Adolescents With Relapsed/Refractory Solid Tumors or Myelodysplastic Syndrome: A Children's Oncology Group Phase I Consortium Report [J].
Berg, Stacey L. ;
Cairo, Mitchell S. ;
Russell, Heidi ;
Ayello, Janet ;
Ingle, Ashish Mark ;
Lau, Henry ;
Chen, Nianhang ;
Adamson, Peter C. ;
Blaney, Susan M. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (03) :316-323
[8]  
Bergmann L, 1995, EXP HEMATOL, V23, P1574
[9]   Human natural killer cell receptors: insights into their molecular function and structure [J].
Biassoni, R ;
Cantoni, C ;
Marras, D ;
Giron-Michel, J ;
Falco, N ;
Moretta, L ;
Dimasi, N .
JOURNAL OF CELLULAR AND MOLECULAR MEDICINE, 2003, 7 (04) :376-387
[10]   BCR/ABL oncogene directly controls MHC class I chain-related molecule A expression in chronic myelogenous leukemia [J].
Boissel, Nicolas ;
Rea, Delphine ;
Tieng, Vannary ;
Dulphy, Nicolas ;
Brun, Manuel ;
Cayuela, Jean-Michel ;
Rousselot, Philippe ;
Tamouza, Ryad ;
Le Bouteiller, Philippe ;
Mahon, Francois-Xavier ;
Steinle, Alexander ;
Charron, Dominique ;
Dombret, Herve ;
Toubert, Antoine .
JOURNAL OF IMMUNOLOGY, 2006, 176 (08) :5108-5116